Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial
Conditions: Sepsis Interventions: Drug: Tocilizumab; Drug: Baricitinib; Drug: Anakinra; Drug: Hydrocortisone; Drug: Hydrocortisone and fludrocortisone; Drug: Heparin; Drug: Low molecular weight heparin; Drug: Recombinant humanThrombomodulin( rhTM); Drug: Sivelestat; Biological: Fresh frozen plasma; Other: Usual care Sponsors: Assistance Publique - H ôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
Conditions: Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult Interventions: Drug: RO7617991; Drug: Tocilizumab Sponsors: Genentech, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Conditions: Orbitopathy, Graves; Thyroid Eye Disease; Ophthalmopathy Interventions: Drug: Tocilizumab Sponsors: Medical University of Warsaw Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)
DiscussionNo effective treatment exists for caAMR at present. Based on the hypothesis that inhibition of IL-6 receptor by tocilizumab will reduce antibody production and reduce antibody-mediated damage, our randomized trial has a potential to provide evidence for a novel treatment strategy for caAMR, therewith slowing the decline in graft function in the long-term.Trial registrationClinicalTrials.gov NCT04561986. Registered on September 24, 2020 (Source: Trials)
Source: Trials - March 22, 2024 Category: Research Source Type: clinical trials
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
Conditions: Systemic Sclerosis; Interstitial Lung Disease Interventions: Drug: Tocilizumab; Drug: Nintedanib; Drug: Standard therapy Sponsors: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland; Medical Research Agency, Poland Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
TocILizumab in aorTitis in GCA (TILT)
Conditions: Giant Cell Arteritis; Aortitis Sponsors: GMIOFrance Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra ® in Healthy Male Participants
Conditions: Healthy Volunteer Interventions: Drug: BIIB800; Drug: Actemra Sponsors: Biogen Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2024 Category: Research Source Type: clinical trials
Plan Development for Giving Teclistamab in the Outpatient Setting
Conditions: Multiple Myeloma; Relapsed Cancer; Refractory Cancer Interventions: Drug: Teclistamab; Drug: Tocilizumab Sponsors: University Health Network, Toronto; Janssen Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Real World Use of Tocilizumab Biosimilar studY
Conditions: Rheumatoid Arthritis Sponsors: Fresenius Kabi SwissBioSim GmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment
Conditions: Interleukin-6; Ischemic Stroke; Endovascular Treatment Interventions: Drug: Tocilizumab; Drug: NaCl 0.9% 100ml Sponsors: Suzhou Municipal Hospital of Anhui Province; Xuanwu Hospital, Beijing Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application
Conditions: COVID-19; Outcome, Fatal; Tocilizumab; Interleukin 6; Critically Ill Interventions: Drug: treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T) Sponsors: University of Ulm Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis —study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study
This study aims to evaluate the efficacy and safety of MTX in maintaining remission in patients with GCA who have previously been treated with GC and at least 6 months with TCZ. We hypothesize that MTX can maintain remission in GCA patients, who have achieved stable remission after treatment with GC and TCZ, and prevent the occurrence of relapses. The study design is a monocentric, randomized, double-blind, placebo-controlled, parallel-group phase II tria l randomizing 40 GCA patients 1:1 into a MTX or placebo arm. Patients will receive 17.5 mg MTX/matching placebo weekly by subcutaneous injection for 12 months, with t...
Source: Trials - January 15, 2024 Category: Research Source Type: clinical trials
Tolerance to Islet Allotransplants in Diabetes
Conditions: Diabetes Mellitus Type 2 - Insulin-Treated Interventions: Biological: ToleraCell-001; Biological: ToleraCell-002; Drug: DFI-105; Drug: Etanercept; Drug: Tocilizumab; Drug: Sirolimus Sponsors: Diabetes Free, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Tocilizumab for TAO
Conditions: Tocilizumab; Thyroid Associated Ophthalmopathy Interventions: Drug: Tocilizumab Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Conditions: Lymphoma Interventions: Drug: Obinutuzumab; Drug: Glofitamab; Drug: Rituximab; Drug: Bendamustine; Drug: Lenalidomide; Drug: Tocilizumab Sponsors: Hoffmann-La Roche Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
